Biohaven Ltd. (BHVN)
NYSE:BHVN
Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$10.98
-$0.59(-1.49%)
At close: 4:00 PM EST
$10.98
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume146.24K
Average Volume (3M)2.20M
Market Cap
$1.53B
Enterprise Value$1.17B
Total Cash (Recent Filing)$347.82M
Total Debt (Recent Filing)$280.27M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 03, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.67
Shares Outstanding150,560,990
10 Day Avg. Volume2,916,684
30 Day Avg. Volume2,203,921
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-567.93
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$18.64Price Target Upside69.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Opakalim Clinical ProgressRobust proof-of-concept epilepsy data demonstrating differentiated efficacy and tolerability materially de-risks a core CNS program. Positive Phase 2 signals and scheduled pivotal readouts in H2 2026 create a clear development pathway and potential future commercial opportunity, strengthening the pipeline's long-term value proposition.
CNS Portfolio With CGRP AssetsA focused CNS franchise with CGRP-targeting migraine assets plus additional neuro programs provides multiple strategic levers: product diversification, cross-program expertise, and potential recurring revenues if clinical and commercial execution succeed. This multi-asset structure supports medium-term resilience and commercialization optionality.
Expanded ATM Equity ProgramAn expanded at-the-market facility materially improves financing optionality, letting management tap equity markets over time rather than a single dilutive event. This structural funding tool reduces immediate liquidity stress and supports continued R&D and operations while management pursues clinical catalysts.
Bears Say
No Revenue; Persistent Large LossesThe absence of material revenue combined with recurring large net losses means the business is not self-sustaining and remains dependent on external capital. Persistent negative earnings increase execution risk for trials and make strategic planning contingent on successful financing or milestone-driven inflections over the medium term.
High And Ongoing Cash BurnDeep, sustained negative operating and free cash flow materially constrain runway and strategic flexibility. Ongoing burn necessitates repeated financing, limits ability to scale programs simultaneously, and raises the probability of program delays or reprioritization if capital markets tighten over the coming months.
Deteriorated Balance Sheet And Higher LeverageA sharp increase in leverage and compressed equity reduce solvency margins and increase financial risk. Elevated debt levels raise interest and covenant exposure, limiting strategic options and increasing reliance on dilutive financing or asset transactions to fund operations and pivotal trials over the medium term.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.53B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Aug 03, 2026 which is in 60 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on May 04, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.831 by -$0.049.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.74.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,560,990 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.831. Following the earnings report the stock price went down -4.241%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.64 (69.73% Upside)
$18.64 (69.73% Upside)
Blogger Sentiment
Neutral
BHVN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 757.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.49%
12-Months-Change
Fundamentals
Return on Equity
-866.46%
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$18.64
▲(69.73% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
11.54% Mutual Funds
33.60% Other Institutional Investors
33.99% Public Companies and
Individual Investors